Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557385 | 0.96 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL2768845 | 0.96 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL1099028 | 0.96 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL7067321 | 0.96 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL5861676 | 0.96 | TK2 (0.34) | TK2TK1 | |
| SCHEMBL26869 | 0.93 | TK2 (0.33) | TK2TK1 | |
| SCHEMBL3033795 | 0.87 | TK2 (0.33) | TK2TK1 | |
| SCHEMBL13383968 | 0.87 | TK2 (0.32) | TK2TK1 | |
| SCHEMBL1277763 | 0.87 | TK2 (0.32) | TK2TK1 | |
| SCHEMBL1408601 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2354148-B1 | Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof | IMANISHI TAKESHI (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7615619-B2 | Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof | TAKESHI IMANISHI (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20060166908-A1 | Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof | BNA INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1481983-A1 | NUCLEOSIDE ANALOGUES AND OLIGONUCLEOTIDE DERIVATIVE COMPRISING NUCLEOTIDE ANALOGUE THEREOF | Imanishi, Takeshi (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166908-A1 | Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof | RNGTT, PNP, NT5C3B | TK2 186/4885TK1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.